BEBT-109

CAT: 0804-HY-W423595-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-W423595-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research[1].
CAS Number
[2050906-40-4]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bebt-109.html
Concentration
10mM
Purity
98.72
Solubility
DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
C=CC(NC1=CC(NC2=NC=CC(N3C=CC4=NC(OC)=CC=C43)=N2)=C(OC)C=C1N(CCN(C)C)C)=O
Molecular Formula
C27H32N8O3
Molecular Weight
516.59
Precautions
H302, H315, H319, H335
References & Citations
[1]Fan F, et al BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Transl Oncol. 2021 Feb;14 (2) :100961.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Related Products

CatalogName
HY-18619-01YL-109
HY-11046AKRP-109
HY-114116-01ML-109
HY-19643JTK-109
HY-118833RAC 109
HY-129603-01SI-109
HY-162360EGFR-IN-109
HY-135307-01SSF-109
HY-15665-01XMD17-109
HY-147835Antibacterial agent 109

Alternative Products

CatalogName
BUP01292-01BEBT-109
MBS5755377BEBT-908
MBS3601852-01XMD17-109
M21973-01ML-109
MBS5767606SI-109
MBS575722YL-109
MBS5775763RAC 109
bs-83459C-01DT-109
sc-52431RhC (109)
202841TAS-109

Popular Products